BioClean BarrierPlus™ Sterile Gauntlet - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BioClean BarrierPlus™ Sterile Gauntlets (S-BBNG) are designed for use in highly controlled environments setting the standard for cleanliness and quality assurance.

Processed in an ISO Class 4 Cleanroom, BioClean BarrierPlus gauntlets have incredibly low levels of particulates and are packed in cleanroom compatible EasyTear™ packaging. Manufactured from white-coloured accelerator-free nitrile (a stretchy, synthetic rubber), they are resistant to a wide range of chemicals, including a selection of commonly-used chemotherapy drugs.  Nitrile also exhibits excellent ESD (Electrostatic Dissipative) properties.

Each BioClean BarrierPlus gauntlet is visually inspected for holes on five separate occasions throughout the manufacturing process, along with water and air pressure testing, to guarantee delivery of a gauntlet 100% free from holes.

BioClean BarrierPlus™ Sterile Gauntlets are available in lengths of up to 840mm (33”) and three port sizes from 150mm to 300mm (6.0” to 12”). 

Also available from the BioClean BarrierPlus range is a sterile mitten (S-BBNM) for use when interventions are rare and access speed is critical, and a sleeve (S-BBNS0) available in lengths of up to 660mm (26”), and suitable for port sizes from 150mm (6.0”) to 300mm (12”).  With a cuff diameter of 90mm (3.5”) the sleeves will fit the majority of available cuff ring systems.

Contact Details:
Nitritex Ltd
Minton Enterprise Park, Oaks Drive
Newmarket, Suffolk, CB8 7YY
www.bioclean.com, info@bioclean.com

Tel: +44 1638 663338
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
FindPharma Custom Search

Click here